Cargando…

Phase III, multi-centre, randomised, double blind, Placebo-controlled study for treatment of juvenile ankylosing spondylitis (AS) with Adalimumab

Detalles Bibliográficos
Autores principales:	Horneff, G, Fitter, S, Huppertz, HI, Foeldvari, I, Kuemmerle-Deschner, K, Kuester, R, Tzaribacev, N, Thon, A, Borte, M, Ganser, G, Trauzeddel, R, Minden, K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194560/ http://dx.doi.org/10.1186/1546-0096-9-S1-P201

Ejemplares similares

Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement
por: Horneff, Gerd, et al.
Publicado: (2012)

Open label multicenter study of once weekly Etanercept 0.8 mg/kg in active polyarticular Juvenile idiopathic arthritis (JIA)
por: Horneff, G, et al.
Publicado: (2008)

Safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis
por: Horneff, G, et al.
Publicado: (2015)

Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab
por: Horneff, Gerd, et al.
Publicado: (2016)

Biologic Therapies in Polyarticular Juvenile Idiopathic Arthritis. Comparison of Long‐Term Safety Data from the German BIKER Registry
por: Klein, Ariane, et al.
Publicado: (2019)

Methotrexate in oligoarticular persistent juvenile idiopathic arthritis
por: Horneff, Gerd, et al.
Publicado: (2014)

Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry
por: Armaroli, Giulia, et al.
Publicado: (2020)

Efficacy and safety of adalimumab in ankylosing spondylitis
por: Mounach, Aziza, et al.
Publicado: (2014)

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
por: Horneff, Gerd, et al.
Publicado: (2017)

Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry
por: Raab, A., et al.
Publicado: (2021)

Adalimumab Therapy Restores the Gut Microbiota in Patients With Ankylosing Spondylitis
por: Chen, Zena, et al.
Publicado: (2021)

Adalimumab Mitigates Lumbar Radiculopathy in a Case of Ankylosing Spondylitis
por: Persaud, Trevor, et al.
Publicado: (2022)

Real‐life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019)

Early Adalimumab and Anti‐Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients
por: Ding, Xiaoliang, et al.
Publicado: (2020)

Adalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy
por: Hennigan, Stephanie, et al.
Publicado: (2007)

Palmoplantar Pustulosis Induced by both Adalimumab and Golimumab for Treatment of Ankylosing Spondylitis
por: Seol, Jung Eun, et al.
Publicado: (2016)

Improvement of overlapping hidradenitis suppurativa and ankylosing spondylitis after the introduction of adalimumab
por: Bosnić, Dubravka, et al.
Publicado: (2016)

Allergic bronchopulmonary aspergillosis in a patient with ankylosing spondylitis treated with adalimumab
por: Suzuki, Yudai, et al.
Publicado: (2021)

Frequency of peripheral diseases in Korean patients with ankylosing spondylitis and the effectiveness of adalimumab
por: Lee, Sang‐Hoon, et al.
Publicado: (2020)

Eosinophilia in a patient with ankylosing spondylitis treated with prolonged adalimumab only
por: He, Junhong, et al.
Publicado: (2022)

Reactive Arthritis Triggered by Adalimumab and Leflunomide in a Patient with Ankylosing Spondylitis
por: Liu, Ying, et al.
Publicado: (2022)

TNF-alpha antagonists for treatment of juvenile ankylosing spondylitis
por: Orbán, I, et al.
Publicado: (2011)

Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven‐Year Interim Results
por: Brunner, Hermine I., et al.
Publicado: (2020)

Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison
por: Maksymowych, Walter P., et al.
Publicado: (2018)

A Case of Adalimumab-Induced Psoriasiform Dermatitis in an Ankylosing Spondylitis Patient: Unusual Progression after Adalimumab Retreatment
por: Yoon, Ji Ha, et al.
Publicado: (2022)

Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis
por: Rudwaleit, Martin, et al.
Publicado: (2010)

The Long-Term Effects of Short-Period Adalimumab Biosimilar Usage in Ankylosing Spondylitis
por: Chopra, Arvind, et al.
Publicado: (2023)

The German version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Holzinger, Dirk, et al.
Publicado: (2018)

Ankylosing Spondylitis
por: Whitfield, A. G. W.
Publicado: (1976)

Lobular capillary hemangioma in a patient with ankylosing spondylitis using adalimumab: an exuberant presentation()()
por: Silva, Thadeu Santos, et al.
Publicado: (2019)

Optical coherence tomography changes in ankylosing spondylitis patients on long-term adalimumab treatment
por: Yavuz, Nurce Cilesizoglu, et al.
Publicado: (2022)

PReS-FINAL-2140: Neutropenia with Tocilizumab (TCZ) treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis (SJIA)
por: De Benedetti, F, et al.
Publicado: (2013)

Adherence, helpfulness and barriers to treatment in juvenile idiopathic arthritis – data from a German Inception cohort
por: Kirchner, Sabine, et al.
Publicado: (2023)

Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis
por: van der Heijde, D, et al.
Publicado: (2008)

Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years
por: van der Heijde, Désirée, et al.
Publicado: (2009)

Ankylosing spondylitis
Publicado: (1980)

Ankylosing spondylitis
por: Edavalath, Mukesh
Publicado: (2010)

Ankylosing Spondylitis
por: Ebrahimiadib, Nazanin, et al.
Publicado: (2021)

A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis
por: Kobayashi, Shigeto, et al.
Publicado: (2011)

Cost of Illness, Quality of Life, and Work Outcomes in Active Ankylosing Spondylitis Patients Treated With Adalimumab in China
por: Tu, Liudan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8ke33da9g3dajb2h13asrg1l2q